Flutiform (fluticasone + formoterol)
Flutiform is an inhalation spray containing fluticasone and formoterol. IRF consider it an equal alternative to the already existing combination treatments. To administer a spray formulation (aerosol) correctly requires better coordination skills than the corresponding discus and turbohaler. Flutiform is approved for treatment of moderate to severe asthma. It is not approved for treatment of COPD.
The formulations 50 mg/5 mg pr. dose and 125 mg/5 mg pr. dose are approved for treatment of adults and children over 12 years. The lowest dose (50 mg) does not seem rational.
The formulation 250 mg/10 mg pr. dose is only approved for adults.
The cost of using Flutiform is currently less than Seretide and Symbicort. It is currently also cheaper than formoterol and fluticasone separately.
Flutiform was approved for marketing September 28th 2012. It is subject to general reimbursement.